Castle Biosciences, Inc.CSTLNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +30.54% | +20.57% | -0.94% | -3.19% | +0.81% |
| Gross Profit Growth | +30.60% | +21.20% | -5.41% | -8.31% | -54.60% |
| EBITDA Growth | +1906.57% | +305.78% | -71.38% | -56.38% | -92.09% |
| Operating Income Growth | +0.00% | +0.00% | -184.82% | -233.96% | -194.49% |
| Net Income Growth | +0.00% | +0.00% | -49.29% | -122.08% | -124.32% |
| EPS Growth | +0.00% | +0.00% | -50.00% | -124.54% | -123.38% |
| EPS Diluted Growth | +0.00% | +0.00% | -51.61% | -122.28% | -124.84% |
| Weighted Average Shares Growth | +3.62% | +4.09% | +4.59% | -10.02% | +4.29% |
| Weighted Average Shares Diluted Growth | +11.26% | +4.09% | +2.81% | -1.12% | -2.87% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +31.09% | +0.00% | -13.24% | -3.03% | +10.53% |
| Free Cash Flow Growth | +13.55% | +0.00% | -38.42% | -54.03% | +17.56% |
| Receivables Growth | +33.72% | +31.98% | +13.75% | -1.55% | -15.30% |
| Inventory Growth | +2.43% | -10.41% | +4.41% | +31.62% | +26.05% |
| Asset Growth | +17.18% | +9.42% | +11.78% | +9.37% | +8.91% |
| Book Value per Share Growth | +12.43% | +5.10% | +2.72% | +17.69% | -0.95% |
| Debt Growth | +71.79% | +3.16% | +48.28% | +38.89% | +40.12% |
| R&D Expense Growth | -10.14% | -8.84% | -9.54% | +5.17% | +15.74% |
| SG&A Expenses Growth | +13.33% | +20.88% | +13.66% | +10.71% | +13.54% |